AstraZeneca PLC
NYSE:AZN · New York Stock Exchange
-$3.04 today
Vol 1.52M · Avg 1.96M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:AZN · Revenue to Net Income
Key Ratios
Analysis
$60.4B of revenue converted into $10.4B of net income for the selected period. Gross margin is 81.7% and net margin is 17.2%, showing how much revenue survives after costs and taxes. EPS is $6.64, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $58.7B +8.6% | $54.1B +18.0% | $45.8B +3.3% | $44.4B +18.5% | $37.4B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $10.6B +4.2% | $10.2B +23.5% | $8.3B -33.3% | $12.4B -0.4% | $12.4B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $48.1B +9.7% | $43.9B +16.8% | $37.5B +17.5% | $32.0B +27.9% | $25.0B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 81.9% +0.8pp | 81.1% -0.8pp | 82.0% +9.9pp | 72.1% +5.3pp | 66.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $14.2B +4.8% | $13.6B +24.2% | $10.9B +12.0% | $9.8B +0.3% | $9.7B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $20.5B +1.4% | $20.2B +11.0% | $18.2B +1.3% | $18.0B +15.4% | $15.6B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $34.4B +1.5% | $33.9B +15.4% | $29.4B +4.1% | $28.2B +17.9% | $23.9B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $5.7B +13.2% | $5.1B +2.7% | $4.9B -6.1% | $5.3B +28.1% | $4.1B | $374.2M | $1.2B | $631.8M |
| EBITDA | $19.8B +28.4% | $15.4B +15.0% | $13.4B +47.7% | $9.1B +77.7% | $5.1B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 33.8% +5.2pp | 28.6% -0.7pp | 29.3% +8.8pp | 20.5% +6.8pp | 13.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | $13.7B +37.4% | $10.0B +22.1% | $8.2B +118.1% | $3.8B +255.8% | $1.1B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 23.4% +4.9pp | 18.5% +0.6pp | 17.9% +9.4pp | 8.5% +5.6pp | 2.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $360.0M +4.3% | $345.0M +14.6% | $301.0M +271.6% | $81.0M +88.4% | $43.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.7B +0.7% | $1.7B +5.9% | $1.6B +19.5% | $1.3B +4.2% | $1.3B | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.3B -2.2% | -$1.3B -1.4% | -$1.3B -3.0% | -$1.3B +4.9% | -$1.3B | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $12.4B +42.7% | $8.7B +26.0% | $6.9B +175.8% | $2.5B +1043.8% | -$265.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 21.1% +5.0pp | 16.1% +1.0pp | 15.1% +9.4pp | 5.6% +6.3pp | -0.7% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $2.2B +31.5% | $1.6B +75.9% | $938.0M +218.4% | -$792.0M -108.4% | -$380.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | $10.3B +45.8% | $7.0B +18.1% | $6.0B +81.1% | $3.3B +2835.7% | $112.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | 17.5% +4.4pp | 13.0% +0.0pp | 13.0% +5.6pp | 7.4% +7.1pp | 0.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $7 +190.7% | $2 -40.4% | $4 +79.7% | $2 +2550.0% | $0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $7 +190.7% | $2 -40.9% | $4 +80.6% | $2 +2537.5% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $1.6B +0.0% | $1.6B -0.8% | $1.6B +0.9% | $1.5B +9.2% | $1.4B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $1.6B -0.1% | $1.6B +0.1% | $1.6B +0.1% | $1.6B +9.3% | $1.4B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Eli Lilly and Company
NYSE:LLY
$1.04T
Johnson & Johnson
NYSE:JNJ
$551.91B
AbbVie Inc.
NYSE:ABBV
$382.35B
Roche Holding AG
RHHBY
$320.95B
Merck & Co., Inc.
NYSE:MRK
$281.78B
Novartis AG
NYSE:NVS
$281.47B
Amgen Inc.
NASDAQ:AMGN
$180.77B
Gilead Sciences, Inc.
NASDAQ:GILD
$152.53B
Pfizer Inc.
NYSE:PFE
$143.80B
Bristol-Myers Squibb Company
NYSE:BMY
$109.97B
GSK plc
NYSE:GSK
$101.97B
Sanofi
NASDAQ:SNY
$101.52B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does AZN generate?
AstraZeneca PLC (AZN) reported $58.74B of revenue in fiscal 2025.
Is AZN profitable?
AstraZeneca PLC (AZN) reported $10.26B of net income, with a net margin of 17.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.